BeOne Medicines Expands U.S. Cancer Access and Manufacturing
SAN CARLOS, Calif., August 31, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company,...
BeOne Medicines
Advertisement
BeOne Reports New Phase 3 Survival Data for ZIIHERA
San Carlos, Calif. – August 31, 2026 BeOne Medicines announced new Phase 3 overall survival data from the HERIZON-GEA-01...
BeOne Wins FDA Approval for TEVIMBRA HER2+ GEA Regimen
SAN CARLOS, Calif., August 25, 2026 BeOne Medicines Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
BeOne Medicines Expands BRUKINSA Access for CLL Patients
SAN CARLOS, Calif. & SEATTLE, Aug. 18, 2026 BeOne Medicines Ltd., together with the BeOne Care Foundation and The...
Silence Therapeutics Reports Positive Divesiran Phase 2 Data
London, August 10, 2026 Silence Therapeutics plc announced positive topline results from the Phase 2 SANRECO trial of divesiran...
Advertisements
BeOne Medicines Partners with Revolution Medicines on RAS Cancer Therapies
San Carlos, Calif. & Redwood City, Calif., August 10, 2026 BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a...
BeOne Medicines Scales Cancer Drug Production in the U.S.
San Carlos, Calif., July 23, 2026 BeOne Medicines announced a $300 million expansion of its flagship Princeton West Innovation...
Senhwa Biosciences Secures NT$500M GEM Investment Deal
TAIPEI, Taiwan & SAN DIEGO, Calif., July 14, 2026 Senhwa Biosciences, Inc. has entered into a significant financing agreement...
BeOne Sets New CLL Benchmark with 78-Month BRUKINSA Data at ASCO 2026
SAN CARLOS, Calif. | May 29, 2026 BeOne Medicines presented groundbreaking long-term data at the 2026 American Society of...
BeOne Medicines Reports Positive Phase 3 HERIZON-GEA Results at ASCO 2026
CHICAGO, Illinois and SAN CARLOS, California — May 27, 2026 BeOne Medicines announced new clinical findings from the Phase...
Advertisement
